# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Citigroup analyst Yigal Nochomovitz maintains Applied Therapeutics (NASDAQ:APLT) with a Buy and raises the price target from...
William Blair has initiated coverage on Applied Therapeutics highlighting its focus on rare diseases such as galactosemia, SORD...
William Blair analyst Tim Lugo initiates coverage on Applied Therapeutics (NASDAQ:APLT) with a Outperform rating.
RBC Capital analyst Brian Abrahams reiterates Applied Therapeutics (NASDAQ:APLT) with a Outperform and maintains $12 price t...